The FDA has approved a higher dose of Wego's HD, an injectable form of the GLP-1 receptor agonist semaglutide, for weight loss at 7.2 mg once weekly, three times the standard strength.[4] The approval was announced by the agency on Thursday, according to MedPage Today. Clinical studies indicate greater weight loss versus lower doses, with safety and tolerability comparable to the 2.4 mg dose.[4] In addition, the FDA approved Wegovy oral tablet with 25 mg of semaglutide once daily to reduce excess weight, maintain weight loss, and reduce the risk of major cardiovascular events.[1][3] The tablet's approval stems from the OASIS program, including OASIS 4, where participants with obesity achieved an average weight loss of 16.6% while on treatment.[1][2][3] Novo Nordisk plans to launch the tablet in the US in early January 2026.[1][2][3][4] It is the first oral GLP-1 therapy approved for weight management.[1][3][4]